Lloyd Klickstein
Adicet BioAbout Lloyd Klickstein
Lloyd Klickstein, M.D., Ph.D., age 61 as of April 15, 2025, has served as an independent director of Adicet Bio (ACET) since August 2024. He is President & CEO of Koslapp Therapeutics, Inc. (since April 2024) and previously founded and led Versanis Bio, Inc. (CEO Feb 2021–Mar 2024), served as Chief Innovation Officer at Adicet Bio (Sep 2020–Feb 2021), Chief Scientific Officer at resTORbio (May 2018–Sep 2020), and Head of Translational Medicine at Novartis Institutes for Biomedical Research; he holds a B.S. from Tufts University and M.D./Ph.D. from Harvard, with clinical training at Brigham and Women’s Hospital and a post-doctoral fellowship at the Center for Blood Research .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Versanis Bio, Inc. | Founding CEO; later President & CEO | Feb 2021–Mar 2024 | Built and led biopharma addressing conditions prevalent in older adults |
| Adicet Bio, Inc. | Chief Innovation Officer | Sep 2020–Feb 2021 | Former executive; familiarity with gamma delta T-cell platform |
| resTORbio, Inc. | Chief Scientific Officer | May 2018–Sep 2020 | Drug discovery leadership; aging-related indications |
| Novartis Institutes for Biomedical Research | Head of Translational Medicine (NIDU/DAx) | Prior to 2018 (dates not disclosed) | Led innovative programs across therapeutic areas |
| Brigham and Women’s Hospital | Academic physician-scientist | Not disclosed | Directed NIH-funded lab; clinical practice in Arthritis Center |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Koslapp Therapeutics, Inc. | President & CEO | Since Apr 2024 | Private biopharma leadership |
| Lupus Foundation of New England | Board Chair | Current (as of 2024) | Non-profit governance role |
| Blade Therapeutics, Inc. | Independent board member | Prior (dates not disclosed) | Prior external board experience |
Board Governance
- Committee memberships: Member, Nominating and Corporate Governance Committee; the committee is chaired by Andrew Sinclair; the board determined all committee members are independent under Nasdaq rules .
- Independence: The board has determined all non-employee directors, excluding the CEO, are independent for Nasdaq/SEC purposes; Klickstein is independent .
- Attendance: The full board met seven times in 2024; each director attended in person or participated in 75% or more of board and applicable committee meetings; all directors attended the 2024 annual meeting .
- Board classification/tenure: Class III director; term expires at the 2027 annual meeting .
Fixed Compensation
| Metric | FY 2024 |
|---|---|
| Cash fees earned ($) | $16,141 |
| Annual board retainer ($) | Program: $40,000 member; $30,000 chair add-on (paid pro rata; Klickstein joined Aug 19, 2024) |
| Committee annual fees ($) | Audit: $7,500 member/$15,000 chair; Compensation: $5,000/$10,000; Nominating & Corporate Governance: $4,000/$8,000 (pro rata) |
Performance Compensation
| Award Type | Grant Date | Shares/Units | Grant-Date Fair Value ($) | Vesting Schedule |
|---|---|---|---|---|
| Initial non-employee director stock option | Aug 19, 2024 (effective appointment) | 70,200 options | $79,636 | 36 equal monthly installments over 3 years, service-contingent |
| Annual non-employee director equity program | At each annual meeting | 26,400 options; 5,900 RSUs (continuing directors) | Not individually disclosed for Klickstein 2024 | Vests in full by the earlier of first anniversary or next annual meeting |
Notes:
- For FY 2024, the director compensation table shows zero stock awards and $79,636 option award fair value for Klickstein; his cash fees reflect pro-rated service from Aug 19, 2024 .
- The equity program aligns director incentives with shareholders; vesting is service-based (no explicit performance metrics for directors) .
Other Directorships & Interlocks
| Company | Public/Private | Role | Potential Interlock/Conflict |
|---|---|---|---|
| Koslapp Therapeutics, Inc. | Private | President & CEO | No ACET-related transaction disclosed; no related-party transactions above thresholds since Jan 1, 2023 |
| Lupus Foundation of New England | Non-profit | Board Chair | Non-profit; no ACET transaction disclosed |
| Blade Therapeutics, Inc. | Private (at time referenced) | Independent board member (prior) | No ACET transaction disclosed |
Expertise & Qualifications
- Deep scientific and translational medicine expertise (Harvard M.D./Ph.D.; Novartis translational leadership; rheumatology/immunology specialization) .
- Biotech operating experience across CSO/CEO roles; familiarity with ACET’s gamma delta T-cell platform from prior Adicet executive role .
- Current leadership in biopharma and non-profit governance, adding external perspective to ACET’s board .
Equity Ownership
| Metric | Apr 17, 2025 | Nov 14, 2025 |
|---|---|---|
| Common shares held | 102,666 | 102,666 |
| Options exercisable within 60 days | 97,550 | 111,200 |
| Total beneficially owned (SEC definition) | 200,216; represents “<1%” of shares outstanding (82,709,625) | 213,866; represents “<1%” of shares outstanding (153,255,581) |
| RSUs vesting within 60 days | Not disclosed for Klickstein | Not disclosed for Klickstein |
| Pledged/hedged shares | Company policy addresses risks of pledging/margins and expressly prohibits derivative transactions; no pledging disclosed for Klickstein |
Governance Assessment
- Independence and committee role: Klickstein is an independent director serving on Nominating & Corporate Governance (not chair). Committee met twice in FY 2024; independence affirmed under Nasdaq/SEC rules, supporting board effectiveness and oversight of nominations and governance processes .
- Engagement: Board met seven times in 2024 with ≥75% attendance across directors; all directors attended the annual meeting—no attendance red flags for Klickstein in his partial-year service .
- Compensation and alignment: FY 2024 compensation was equity-heavy (cash $16,141 vs option grant fair value $79,636), with standard service-based vesting; annual program provides 26,400 options and 5,900 RSUs for continuing directors, reinforcing alignment via equity ownership rather than meeting fees .
- Ownership: Beneficial ownership is <1%; holdings include both common shares and options exercisable within 60 days; no disclosed pledging or related-party transactions involving Klickstein since Jan 1, 2023—reduces conflict risk .
- Potential conflicts: External CEO role at Koslapp Therapeutics and non-profit chair role present outside commitments but no ACET-related transactions or disclosed conflicts; governance committee responsibilities include oversight of nominations and annual evaluations, providing a check on any conflicts .
RED FLAGS: None disclosed specific to Klickstein—no related-party transactions, no attendance issues, no hedging/derivative use. Company-wide, derivative transactions are prohibited; pledging/margin risks are addressed in policy .